(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied.
Related Topics
OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued
OCRA Invests More than $10.8 Million Toward Research, Part of $14.5 Million Commitment in 2025
In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy. This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued